Cubist Systematic Strategies, LLC Krystal Biotech, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $776,483 - $1.29 Million	7,189 New	7,189 $1.28 Million
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $94,107 - $109,551	1,300 New	1,300 $104,000
Q1 2022 May 16, 2022	SELL	$51.99 - $72.11 $232,759 - $322,836	-4,477 Reduced 99.18%	37 $2,000
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $22,054 - $48,884	554 Added 13.99%	4,514 $316,000
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $205,959 - $284,209	3,960 New	3,960 $207,000
Q2 2021 Aug 16, 2021	SELL	$62.14 - $81.82 $2,982 - $3,927	-48 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $2,852 - $4,102	48 New	48 $4,000
Q4 2020 Feb 16, 2021	SELL	$40.64 - $61.38 $8,128 - $12,276	-200 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$37.76 - $48.49 $7,552 - $9,698	200 New	200 $9,000
Q2 2019 Aug 14, 2019	SELL	$27.2 - $41.2 $13,600 - $20,600	-500 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$19.86 - $32.9 $9,930 - $16,450	500 New	500 $16,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.89B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.